Human Chorionic Gonadotropin Market Size (By Technology: Natural Source Extraction, and Recombinant Technology; By Therapeutic Area: Female Infertility Treatment, Male Hypogonadism, Oligospermia Treatment, and Others; By End-User: Fertility Clinics, Research Institutions, and Others) – Global Industry Analysis, Market Size, Opportunities and Forecast 2021 – 2028

Category : Healthcare and Pharmaceuticals | Delivery Format : PDF | Status: Published | Pages : 250

The global human chorionic gonadotropin market accounted for US $ 874 Mn in 2020 and is expected to reach US $ 1,534 Mn by 2028 with a considerable CAGR of 7.4% during the predicted period of 2021 to 2028.

Human chorionic gonadotropin (hCG) is a hormone that is produced primarily by the placenta's syncytiotrophoblastic cells during pregnancy. To keep the pregnancy going, the hormone causes the corpus luteum to generate progesterone. Considerable amounts of hCG are produced by the pituitary gland, liver, and colon. It is made up of cells that eventually produce the placenta that also gives nutrition to the fertilized egg and transmits to the wall of the uterine. hCG is a dimer composed of 92 amino acid alpha-subunits and 145 amino acid beta-subunit that are inimitable to hCG. Moreover, follicle-stimulating hormone (FSH), luteinizing hormone (LH), and thyroid-stimulating hormone (TSH) all have the same alpha-subunit.

Drivers

  • The significant increase in infertility issues among men and women has fueled the market growth
  • The rise in the prevalence of hypogonadism in the geriatric population is propelling the global hCG market

Restraint

  • The availability of substitutes, as well as FDA cautions and warnings about the side effects of hCG, impede the market growth

Opportunity

The growing popularity of fertility treatments, as well as the availability of advanced IVF facilities and treatment options, is expected to provide lucrative opportunities for the market in forecasting years

Report Coverage: 

Market Human Chorionic Gonadotropin Market
Market Size 2020 US$ 874 Mn
Market Forecast 2028 US$ 1,534 Mn
CAGR 7.4% During 2021 - 2028
Analysis Period 2017 - 2028
Base Year 2020
Forecast Data 2021 - 2028
Segments Covered By Technology, By Therapeutic Area, By End-User and By Geography
Regional Scope North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
Key Companies Profiled Bristol Myers Squibb Company, Cigna, Merck & Co., Inc., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd, Ferring Pharmaceuticals Inc, Scripps Laboratories, Lee BioSolutions Inc., Sanzyme, and LUPIN.
Report Coverage
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis
Customization Scope

10 hrs of free customization and expert consultation

The rising prevalence of hypogonadism-related disorders in men, particularly in elderly men, is a major driver of the human chorionic gonadotropin (hCG) industry

In recent, physicians face a unique problem when it comes to hypogonadism in men who want to keep their fertility. The population of young men with hypogonadism has risen dramatically in the last decade. These men are generally operated with testosterone replacement therapy (TRT) that results in azoospermia and in the worst-case scenario, infertility. However, human chorionic gonadotropin therapy can be helpful for hypogonadal men to reestablish or balance spermatogenesis.

With a rise in the prevalence of hypogonadism in the younger men population and the use of anabolic steroids, the importance of therapeutic human chorionic gonadotropin (hCG) treatment has grown exponentially over the last few decades. However, between 2001 and 2011, the number of men using testosterone replacement therapy (TRT) increased threefold overall, and fourfold among men aged 40–49. Furthermore, the total prevalence of hypogonadism in American men is 7% in men under the age of 40 and 38% in men over the age of 45. Anabolic androgenic steroid (AAS) use has been estimated to be as high as 3 million among American men, with a lifetime prevalence of use ranging from 3% to 4.2%. This rise has coincided with a steady rise in paternity age, posing a new challenge in treating hypogonadism and conserving fertility.

Market Segmentation

Market By Technology

  • Natural Source Extraction
  • Recombinant Technology

Based on the technology, the natural source extraction segment is expected to have the largest human chorionic gonadotropin market share over the forecast period. The popularity of naturally extracted hCG hormone products is increasing due to the introduction of new products and widespread adoption, which will also contribute to the segment's growth during the forecast period. For nearly three decades, hCG has been extracted naturally from pregnant women's urine and used to induce midcycle follicle evolution and ovulatory in women undergoing fertility treatments. Furthermore, recombinant HCG (rHCG) has recently been developed as an alternative to naturally extracted hCG for the final maturation of oocytes in women undergoing in-vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).

Market By Therapeutic Area

  • Female Infertility Treatment
  • Male Hypogonadism
  • Oligospermia Treatment
  • Others

Female infertility treatment held the largest market share in 2020 and is expected to continue to do so throughout the forthcoming years. This is due to an increase in infertility-related issues in females, such as polycystic ovarian syndrome (PCOS). Infertility in females can be caused by a variety of factors, including tubal disorders such as a blocked fallopian tube, polycystic ovary syndrome, uterine disorders, other follicular disorders, or an endocrine system disorder. Human chorionic gonadotropin (hCG) is a hormone that can be used to treat infertility issues and help to improve the chances of pregnancy as part of an IVF or ART cycle. With the increasing incidence of infertility in females around the globe, the demand for effective treatment is anticipated to propel the growth of the market.

Market By End-User

  • Fertility Clinics
  • Research Institutions
  • Others

Fertility clinics provide services to help with the treatment of infertility. These services include in vitro fertilization (IVF), surrogacy, artificial insemination, and other techniques that aid in the resolution of infertility problems among marriages, single mothers, as well as the LGBT community. Even so, technological developments in assisted reproductive techniques, as well as an increase in awareness about infertility treatment, are anticipated to propel the growth of the fertility clinics segment during the forecast period.

Human Chorionic Gonadotropin Market Regional Overview

North America

  • U.S.
  • Canada

Europe

  • U.K.
  • Germany
  • France
  • Spain
  • Rest of Europe

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

Asia-Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific

Middle East & Africa

  • GCC
  • South Africa
  • Rest of Middle East & Africa

North America contributed the maximum revenue in 2020 and is expected to continue its dominance throughout the upcoming years. This is due to a significant rise in the number of infertility-related problems in both men and women in North America. According to the American Society for Reproductive Medicine study, the male partner is responsible for infertility in approximately 40% of infertile couples, and approximately 85–90% of them are treated with drugs or surgery. Moreover, in the United States, approximately 300 per 100,000 women use assisted reproductive technologies (ART) to treat infertility each year. This is expected to drive market growth in the North American region.

Competitive Landscape

Some of the key players in global human chorionic gonadotropin market are Bristol Myers Squibb Company, Cigna, Merck & Co., Inc., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd, Ferring Pharmaceuticals Inc, Scripps Laboratories, Lee BioSolutions Inc., Sanzyme, and LUPIN.

Frequently Asked Questions

The estimated value of global recycled carbon fiber market in 2020 was accounted to be US$ 874 Mn and market projected to reach US$ 1,534 by 2028

The projected CAGR of recycled carbon fiber market during the analysis period of 2021 to 2028 is 7.4%

The prominent players of the global human chorionic gonadotropin market involve Merck & Co., Inc., Bristol Myers Squibb Company, Fresenius Kabi AG, Cigna, Sun Pharmaceutical Industries Ltd, Ferring Pharmaceuticals Inc, Scripps Laboratories, Lee BioSolutions Inc., Sanzyme, and LUPIN.

North America held the dominating share for human chorionic gonadotropin during the analysis period of 2021 to 2028

Asia Pacific region exhibited fastest growing CAGR for human chorionic gonadotropin during the analysis period of 2021 to 2028

The significant increase in infertility issues among men and women and the rise in the prevalence of hypogonadism in the geriatric population are the major factors driving the global human chorionic gonadotropin market.

Based on therapeutic area, female infertility treatment segment held the maximum share for human chorionic gonadotropin market in 2020.

Cart Summary